Novel combination of serum microRNA for detecting breast cancer in the early stage

MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non‐cancer controls, 451 from patients with other types of cancers, and 63 from patients with non‐breast benign diseases. The samples were divided into a training cohort including non‐cancer controls, other cancers and breast cancer, and a test cohort including non‐cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non‐breast cancer, and a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).

[1]  H. Davson.  Blood–brain barrier , 1977, Nature.

[2]  A. Madabhushi,et al.  Investigating the Efficacy of Nonlinear Dimensionality Reduction Schemes in Classifying Gene and Protein Expression Studies , 2008, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[3]  Ulus Atasoy,et al.  Circulating microRNAs in breast cancer and healthy subjects , 2009, BMC Research Notes.

[4]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[5]  Brigitte Rack,et al.  Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer , 2010, Breast Cancer Research.

[6]  M. L. Hastings,et al.  Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.

[7]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[8]  Sota Asaga,et al.  Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. , 2011, Clinical chemistry.

[9]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[10]  Martin Reczko,et al.  DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways , 2012, Nucleic Acids Res..

[11]  Yu Sun,et al.  Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer , 2012, PloS one.

[12]  Teruhiko Yoshida,et al.  Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells , 2012, Cancer science.

[13]  Yingjian Chen,et al.  Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[14]  T. Stopka,et al.  Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum , 2014, BMC Cancer.

[15]  Axel Benner,et al.  Circulating microRNAs in plasma as early detection markers for breast cancer , 2013, International journal of cancer.

[16]  Ying Zhu,et al.  MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers , 2014, BMC Cancer.

[17]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[18]  Michael Golatta,et al.  Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer , 2013, PloS one.

[19]  S. Zhang,et al.  Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[20]  Cristina Rodríguez-Padilla,et al.  Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers , 2013, Disease markers.

[21]  Ava Kwong,et al.  Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection , 2013, PloS one.

[22]  N. Kosaka,et al.  Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells , 2014, Science Signaling.

[23]  H. Binder,et al.  Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study , 2014, Molecular oncology.

[24]  Qiang Hu,et al.  Circulating miR-148b and miR-133a as biomarkers for breast cancer detection , 2014, Oncotarget.

[25]  Yusuke Yoshioka,et al.  Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier , 2015, Nature Communications.

[26]  Motohiro Kojima,et al.  MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers , 2015, PloS one.